Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8873)
All Articles published online
|
Publishing Process of This Article
|
Apr 7, 2018 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v24/i13/1440.htm |
| Number | Citing Articles |
| 1 |
Fu-Rong Sun, Bing-Yuan Wang. Alcohol and Metabolic-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2021.00173
|
| 2 |
Wasit Wongtrakul, Sorachat Niltwat, Phunchai Charatcharoenwitthaya. The Effects of Modest Alcohol Consumption on Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.744713
|
| 3 |
James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. The Lancet Gastroenterology & Hepatology 2024; 9(2): 159 doi: 10.1016/S2468-1253(23)00275-3
|
| 4 |
Gianni TESTINO, Rinaldo PELLICANO. Corrected and republished from: Metabolic associated liver disease. Panminerva Medica 2023; 65(3) doi: 10.23736/S0031-0808.23.04850-4
|
| 5 |
Aitor Odriozola, Alvaro Santos-Laso, María del Barrio, Joaquín Cabezas, Paula Iruzubieta, María Teresa Arias-Loste, Coral Rivas, Juan Carlos Rodríguez Duque, Ángela Antón, Emilio Fábrega, Javier Crespo. Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review. International Journal of Molecular Sciences 2023; 24(9): 7791 doi: 10.3390/ijms24097791
|
| 6 |
Louise Magherman, Robbe Van Parys, Nele S. Pauwels, Xavier Verhelst, Lindsey Devisscher, Hans Van Vlierberghe, Anja Geerts, Sander Lefere. Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2023; 57(8): 820 doi: 10.1111/apt.17388
|
| 7 |
Yu-Hyeon Yi, Yun-Jin Kim, Sang-Yeoup Lee, Byung-Mann Cho, Young-Hye Cho, Jeong-Gyu Lee. Health behaviors of Korean adults with hepatitis B: Findings of the 2016 Korean National Health and Nutrition Examination Survey. World Journal of Gastroenterology 2018; 24(28): 3163-3170 doi: 10.3748/wjg.v24.i28.3163
|
| 8 |
Grażyna Kubiak-Tomaszewska, Piotr Tomaszewski, Jan Pachecka, Marta Struga, Wioletta Olejarz, Magdalena Mielczarek-Puta, Grażyna Nowicka. Molecular mechanisms of ethanol biotransformation: enzymes of oxidative and nonoxidative metabolic pathways in human. Xenobiotica 2020; 50(10): 1180 doi: 10.1080/00498254.2020.1761571
|
| 9 |
Min Yao, Wenjie Zheng, Li Wang, Miao Fang, Zhizhen Dong, Dengfu Yao. Neoplasm. 2018; doi: 10.5772/intechopen.77400
|
| 10 |
Xiaojing Wang, Liangjing Wang, Lin Geng, Naoki Tanaka, Bin Ye. Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner. International Journal of Molecular Sciences 2023; 24(6): 5843 doi: 10.3390/ijms24065843
|
| 11 |
Ruifang Li, Jie Liu, Ping Han, Ruifang Shi, Lili Zhao, Jia Li. Associations between abdominal obesity indices and pathological features of non‐alcoholic fatty liver disease: Chinese visceral adiposity index. Journal of Gastroenterology and Hepatology 2023; 38(8): 1316 doi: 10.1111/jgh.16196
|
| 12 |
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison. NAFLD‐related hepatocellular carcinoma: The growing challenge. Hepatology 2023; 77(1): 323 doi: 10.1002/hep.32542
|
| 13 |
Lampros Chrysavgis, Ilias Giannakodimos, Panagiota Diamantopoulou, Evangelos Cholongitas. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World Journal of Gastroenterology 2022; 28(3): 310-331 doi: 10.3748/wjg.v28.i3.310
|
| 14 |
Michelle T. Long, Joseph M. Massaro, Udo Hoffmann, Emelia J. Benjamin, Timothy S. Naimi. Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2020; 18(8): 1831 doi: 10.1016/j.cgh.2019.11.022
|
| 15 |
Limin Cao, Yu An, Huiyuan Liu, Jinguo Jiang, Wenqi Liu, Yuhan Zhou, Mengyuan Shi, Wei Dai, Yanling Lv, Yuhong Zhao, Yanhui Lu, Liangkai Chen, Yang Xia. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. BMC Medicine 2024; 22(1) doi: 10.1186/s12916-024-03315-0
|
| 16 |
Jordi Gratacós-Ginès, Silvia Ariño, Pau Sancho-Bru, Ramon Bataller, Elisa Pose. MetALD: clinical aspects, pathophysiology and treatment. JHEP Reports 2024; : 101250 doi: 10.1016/j.jhepr.2024.101250
|
| 17 |
Michiharu Komatsu, Naoki Tanaka, Takefumi Kimura, Naoyuki Fujimori, Kenji Sano, Akira Horiuchi, Ayumi Sugiura, Tomoo Yamazaki, Soichiro Shibata, Satoru Joshita, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka. Miglitol attenuates non‐alcoholic steatohepatitis in diabetic patients. Hepatology Research 2018; 48(13): 1092 doi: 10.1111/hepr.13223
|
| 18 |
Taiki Okumura, Takefumi Kimura, Yuki Ichikawa, Takanobu Iwadare, Shun-ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Takuro Uchida, Sai P. Pydi, Naoki Tanaka, Takeji Umemura. Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-76532-5
|
| 19 |
Shiyu Xiao, Ya Liu, Xiliang Fu, Tong Chen, Wenhui Xie. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis. The American Journal of Medicine 2024; 137(11): 1072 doi: 10.1016/j.amjmed.2024.06.031
|
| 20 |
Naoyuki Fujimori, Takefumi Kimura, Naoki Tanaka, Tomoo Yamazaki, Taiki Okumura, Hiroyuki Kobayashi, Shun‐ichi Wakabayashi, Yuki Yamashita, Ayumi Sugiura, Jonathan Pham, Sai P. Pydi, Kenji Sano, Satoru Joshita, Takeji Umemura. 2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease. Hepatology Research 2022; 52(4): 352 doi: 10.1111/hepr.13745
|
| 21 |
Catalina M. Mascaró, Cristina Bouzas, Sofía Montemayor, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Pere-Antoni Borràs, J. Alfredo Martínez, Josep A. Tur. Association between Stages of Hepatic Steatosis and Physical Activity Performance in Adults with Metabolic Syndrome: A Cross-Sectional Analysis in FLIPAN Study. Nutrients 2022; 14(9): 1790 doi: 10.3390/nu14091790
|
| 22 |
Anand V. Kulkarni, Shiv Kumar Sarin. The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism 2023; 14 doi: 10.1177/20420188231178370
|
| 23 |
Ryuki Hashida, Pegah Golabi, Janus Ong, Takumi Kawaguchi, Zobair M. Younossi. Alcohol and Metabolic Syndrome Interaction. Clinics in Liver Disease 2024; 28(4): 601 doi: 10.1016/j.cld.2024.06.002
|
| 24 |
Patrik Nasr, Cecilia Jönsson, Mattias Ekstedt, Stergios Kechagias. Non-metabolic causes of steatotic liver disease. Metabolism and Target Organ Damage 2023; 3(4) doi: 10.20517/mtod.2023.20
|
| 25 |
Shen Li, Antonio Saviano, Derek J. Erstad, Yujin Hoshida, Bryan C. Fuchs, Thomas Baumert, Kenneth K. Tanabe. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. Journal of Clinical Medicine 2020; 9(12): 3817 doi: 10.3390/jcm9123817
|
| 26 |
Daniel Q. Huang, Hashem B. El-Serag, Rohit Loomba. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology 2021; 18(4): 223 doi: 10.1038/s41575-020-00381-6
|
| 27 |
Stergios Kechagias, Patrik Nasr, Julia Blomdahl, Mattias Ekstedt. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020; 111: 154183 doi: 10.1016/j.metabol.2020.154183
|
| 28 |
Pan Diao, Xiaojing Wang, Fangping Jia, Takefumi Kimura, Xiao Hu, Saki Shirotori, Ibuki Nakamura, Yoshiko Sato, Jun Nakayama, Kyoji Moriya, Kazuhiko Koike, Frank J Gonzalez, Toshifumi Aoyama, Naoki Tanaka. A saturated fatty acid-rich diet enhances hepatic lipogenesis and tumorigenesis in HCV core gene transgenic mice. The Journal of Nutritional Biochemistry 2020; 85: 108460 doi: 10.1016/j.jnutbio.2020.108460
|
| 29 |
Xiao Hu, Xiaojing Wang, Fangping Jia, Naoki Tanaka, Takefumi Kimura, Takero Nakajima, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Frank J Gonzalez, Jun Nakayama, Toshifumi Aoyama. A trans-fatty acid-rich diet promotes liver tumorigenesis in HCV core gene transgenic mice. Carcinogenesis 2020; 41(2): 159 doi: 10.1093/carcin/bgz132
|
| 30 |
Fangping Jia, Pan Diao, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Makoto Nakamuta, Ibuki Nakamura, Saki Shirotori, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Frank J. Gonzalez, Jun Nakayama, Toshifumi Aoyama, Naoki Tanaka. Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice. Liver Cancer 2020; 9(5): 529 doi: 10.1159/000508308
|
| 31 |
Naoyuki Fujimori, Naoki Tanaka, Takefumi Kimura, Kenji Sano, Akira Horiuchi, Naoyuki Kato, Yoshiyuki Takahashi, Naoya Kuribayashi, Ayumi Sugiura, Tomoo Yamazaki, Satoru Joshita, Takeji Umemura, Akihiro Matsumoto, Eiji Tanaka. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. Clinical Journal of Gastroenterology 2020; 13(1): 83 doi: 10.1007/s12328-019-01018-1
|
| 32 |
Fouad Jaber, George Cholankeril, Hashem B El-Serag. Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. Journal of the Canadian Association of Gastroenterology 2024; 7(5): 331 doi: 10.1093/jcag/gwae025
|
| 33 |
Stergios A. Polyzos, Lampros Chrysavgis, Ilias D. Vachliotis, Evangelos Chartampilas, Evangelos Cholongitas. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy. Seminars in Cancer Biology 2023; 93: 20 doi: 10.1016/j.semcancer.2023.04.010
|
| 34 |
Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu. The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study. PLOS Medicine 2023; 20(6): e1004244 doi: 10.1371/journal.pmed.1004244
|
| 35 |
Shogo Takahashi, Naoki Tanaka, Tatsuki Fukami, Cen Xie, Tomoki Yagai, Donghwan Kim, Thomas J. Velenosi, Tingting Yan, Kristopher W. Krausz, Moshe Levi, Frank J. Gonzalez. Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development. Hepatology Communications 2018; 2(12): 1567 doi: 10.1002/hep4.1263
|
| 36 |
Julia Blomdahl, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD. Hepatology Communications 2023; 7(1): e0003 doi: 10.1097/HC9.0000000000000003
|
| 37 |
Claudia Maccali, Isabel V. A. Pereira, José Tadeu Stefano, Claudia P. Oliveira. Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores. Current Hepatology Reports 2023; 22(4): 228 doi: 10.1007/s11901-023-00623-6
|
| 38 |
Haisong Hou, Liu Liang, Lihong Deng, Wanping Ye, Yuanzhang Wen, Jun Liu. Comparison of Clinical Manifestations and Related Factors of Hepatocellular Carcinoma with Chronic Hepatitis B. International Journal of General Medicine 2024; : 2877 doi: 10.2147/IJGM.S464083
|
| 39 |
Xiaojing Wang, Naoki Tanaka, Xiao Hu, Takefumi Kimura, Yu Lu, Fangping Jia, Yoshiko Sato, Jun Nakayama, Kyoji Moriya, Kazuhiko Koike, Toshifumi Aoyama. A high-cholesterol diet promotes steatohepatitis and liver tumorigenesis in HCV core gene transgenic mice. Archives of Toxicology 2019; 93(6): 1713 doi: 10.1007/s00204-019-02440-7
|
| 40 |
Elif Inan-Eroglu, Bo-Huei Huang, Matthew N. Ahmadi, Nathan Johnson, Emad M. El-Omar, Emmanuel Stamatakis. Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank. European Journal of Clinical Nutrition 2022; 76(1): 74 doi: 10.1038/s41430-021-00923-4
|
| 41 |
Naoki Tanaka, Takefumi Kimura, Naoyuki Fujimori, Tadanobu Nagaya, Michiharu Komatsu, Eiji Tanaka. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World Journal of Gastroenterology 2019; 25(2): 163-177 doi: 10.3748/wjg.v25.i2.163
|
| 42 |
Hongliang Xue, Liqing Wang, Yuankai Wu, Xinyu Liu, Jingcheng Jiang, Sun On Chan, Xu Chen, Wenhua Ling, Chao Yu. Association of moderate alcohol intake with the risks of cirrhosis and steatotic liver disease: Results from a large population-based cohort study. Clinical Nutrition 2024; 43(12): 75 doi: 10.1016/j.clnu.2024.10.014
|
| 43 |
Francesca Cainelli, Titya Thao, Carolyne Pung, Sandro Vento. Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients. Frontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00014
|
| 44 |
Silvia Andaloro, Fabrizio Mancuso, Luca Miele, Giovanni Addolorato, Antonio Gasbarrini, Francesca Romana Ponziani. Effect of Low-Dose Alcohol Consumption on Chronic Liver Disease. Nutrients 2024; 16(5): 613 doi: 10.3390/nu16050613
|
| 45 |
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, Ramón Bataller, Marco Arrese. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 2023; 20(12): 764 doi: 10.1038/s41575-023-00822-y
|
| 46 |
Masayuki Ueno, Haruhiko Takeda, Atsushi Takai, Hiroshi Seno. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World Journal of Gastroenterology 2022; 28(27): 3410-3421 doi: 10.3748/wjg.v28.i27.3410
|
| 47 |
Hannes Hagström, Hannes Hegmar, Christophe Moreno. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease. United European Gastroenterology Journal 2024; 12(2): 168 doi: 10.1002/ueg2.12524
|
| 48 |
Pan Diao, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Takero Nakajima, Toshifumi Aoyama, Kyoji Moriya, Kazuhiko Koike, Naoki Tanaka. Mechanisms of Steatosis-Derived Hepatocarcinogenesis: Lessons from HCV Core Gene Transgenic Mice. Engineering 2021; 7(12): 1797 doi: 10.1016/j.eng.2021.08.019
|
| 49 |
Takefumi Kimura, Naoki Tanaka, Naoyuki Fujimori, Tomoo Yamazaki, Takahito Katsuyama, Yuichi Iwashita, Jonathan Pham, Satoru Joshita, Sai P. Pydi, Takeji Umemura. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver International 2021; 41(3): 505 doi: 10.1111/liv.14776
|
| 50 |
Ana Sandoval-Rodriguez, Aldo Torre, Juan Armendariz-Borunda. Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.892495
|
| 51 |
Peng‐sheng Ting, Wei‐Ting Lin, Chiung‐Kuei Huang, Hui‐Yi Lin, Tung‐Sung Tseng, Po‐Hung Chen. Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease. Alcohol: Clinical and Experimental Research 2024; 48(1): 88 doi: 10.1111/acer.15220
|
| 52 |
Helen Jarvis, Hannah O'Keefe, Dawn Craig, Daniel Stow, Barbara Hanratty, Quentin M Anstee. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022; 12(1): e049767 doi: 10.1136/bmjopen-2021-049767
|
| 53 |
Fredrik Åberg, Christopher D. Byrne, Carlos J. Pirola, Ville Männistö, Silvia Sookoian. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. Journal of Hepatology 2023; 78(1): 191 doi: 10.1016/j.jhep.2022.08.030
|
| 54 |
Fredrik Åberg, Martti Färkkilä, Ville Männistö. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcoholism: Clinical and Experimental Research 2020; 44(2): 384 doi: 10.1111/acer.14271
|
| 55 |
Hannes Hagström, Stergios Kechagias, Mattias Ekstedt. Risk for hepatic and extra‐hepatic outcomes in nonalcoholic fatty liver disease. Journal of Internal Medicine 2022; 292(2): 177 doi: 10.1111/joim.13343
|
| 56 |
Nobuharu Tamaki, Takefumi Kimura, Shun‐Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi. Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality. Alimentary Pharmacology & Therapeutics 2024; 60(1): 61 doi: 10.1111/apt.18015
|
| 57 |
Takanobu Iwadare, Takefumi Kimura, Ayumi Sugiura, Taiki Okumura, Shun‐ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita, Naoki Tanaka, Takeji Umemura. Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy. Journal of Viral Hepatitis 2024; doi: 10.1111/jvh.14025
|